BACKGROUND: Low-level laser therapy (LLLT) has been reported to relieve pain, free of side effects. However, the mechanisms underlying LLLT are not well understood. Recent studies have also demonstrated that opioid-containing immune cells migrate to inflamed sites and release ␤-endorphins to inhibit pain as a mode of peripheral endogenous opioid analgesia. We investigated whether pre-irradiation of blood by LLLT enhances peripheral endogenous opioid analgesia. METHODS: The effect of LLLT pretreatment of blood on peripheral endogenous opioid analgesia was evaluated in a rat model of inflammation. Additionally, the effect of LLLT on opioid production was also investigated in vitro in rat blood cells. The expression of the ␤-endorphin precursors, proopiomelanocortin and corticotrophin releasing factor, were investigated by reverse transcription polymerase chain reaction. RESULTS: LLLT pretreatment produced an analgesic effect in inflamed peripheral tissue, which was transiently antagonized by naloxone. Correspondingly, ␤-endorphin precursor mRNA expression increased with LLLT, both in vivo and in vitro. CONCLUSION: These findings suggest that that LLLT pretreatment of blood induces analgesia in rats by enhancing peripheral endogenous opioid production, in addition to previously reported mechanisms.
Europe and Russia in the early 1960s. LLLT is principally used to treat pain by using red or near infrared monochromatic light sources emitting low energies (in the milliwatt range). [1] [2] [3] The irradiation in LLLT uses a local high photon density monochromatic light source. 4 Previous work has proposed that any biologic effects are secondary to the direct effects of photonic radiation and are not the result of thermal processes. 5 Studies of the effect of LLLT on the peripheral nervous system have also been encouraging. In a double-blind, controlled trial, LLLT and transcutaneous electric nerve stimulation both significantly reduced pain scores and improved median sensory latency in patients with carpal tunnel syndrome. 6 Pinheiro et al. also demonstrated a reduction of pain-related symptoms after treating patients with maxillofacial pain disorders, including trigeminal neuralgia, with laser therapy in a nonrandomized, unblinded study. 7 In the case of neuropathic pain, LLLT may mediate analgesia by releasing local neurotransmitters such as serotonin, 1 promoting endorphin release, 8 or through antiinflammatory effects. 9 Athermic laser irradiation was found to induce a significant increase in skin microcirculation in patients with diabetic microangiopathy, as measured by infrared thermography. 10 At the same time, pain is effectively controlled by various endogenous mechanisms. Studies have shown that these mechanisms are not restricted to the central nervous system. Rather, intrinsic pain control can occur also in the peripheral nervous system, mediated by an interaction between immune cells and sensory neuron terminals. 11 Under stressful conditions or in response to corticotropin-releasing factor (CRF), circulating leukocytes can secrete opioids after migrating to inflamed tissues. 12 Upon preferentially migrating to inflamed sites, the released ␤-endorphins activate pain-inhibiting opioid receptors. 13, 14 The major endogenous opioid, ␤-endorphin, derives from proopiomelanocortin (POMC), which may be a marker for induced analgesia. 15 The interaction between immune cell-derived opioids and opioid receptors, localized on sensory nerve terminals, can result in clinically measurable peripheral endogenous opioid analgesia.
In several studies, LLLT has been shown to affect several immunologic reactions. 18 -20 The present study investigated whether LLLT pretreatment of blood induces immune cells to express ␤-endorphins at inflamed sites, thereby enhancing peripheral endogenous opioid analgesia.
METHODS

Animals
The study protocol was approved by the Animal Care and Use Committee of Oita University (Oita, Japan). Experiments were performed on male SpragueDawley rats (250 -300 g; Japan Charles River, Yokohama), individually housed in cages lined with sawdust. Standard laboratory rodent food and water were available ad libitum. Room temperature and relative humidity were maintained at 22 Ϯ 0.5°C and 60%, respectively, under a 12-h light and dark cycle. All testing was conducted in the light phase, using separate groups of animals. All experiments were conducted in accordance with the Institutional Committee for the Care and Use of Animals and the guidelines on ethical standards for investigations on experimental pain in animals. 21 
Drugs
Freund's complete adjuvant (FCA) was purchased from PIERCE (Rockford, IL). Naloxone hydrochloride (naloxone) was purchased from Sigma Chemical Co. (St. Louis, MO).
Induction of Adjuvant-Induced Peripheral Inflammation
In both control and LLLT animals, unilateral hindpaw inflammation was induced by injecting 0.15 mL of FCA into the right hindpaw. All groups were injected with 0.15 mL of saline into the left hindpaw. Injections were performed under brief sevoflurane anesthesia (Maruishi CO, Osaka, Japan).
LLLT
An infrared gallium aluminum arsenide diode laser device (Mochida Siemens Medical Systems CO, Tokyo, Japan) with a wavelength of 830 nm and a maximum power output of 1000 mW was used for treatments. Rats were randomly assigned to three groups (n ϭ 20 per group): 1) saline group: receiving saline injection with no LLLT treatment; 2) control group: receiving placebo laser treatment before FCA injection; or 3) LLLT group: receiving 5 min of LLLT administered to blood (300 J total dose) before FCA injection. Under the 3% sevoflurane anesthesia, venous blood (2 mL) was obtained from the left external jugular vein and treated with placebo laser or LLLT, in the presence of heparin anticoagulation. After treatment, blood was re-transfused back into the experimental animal. This process of extrapolation, laser or placebo treatment, and re-infusion was performed five times for both control and LLLT groups, 4 h before the induction of peripheral inflammation with FCA injection.
Measurement of Withdrawal Latency by Plantar Test
Withdrawal latency was determined by the plantar test, using the method modified by Hargreaves et al. 22 This variable was assayed 24 h before LLLT or placebo treatment, and then 12 h, 24 h, and 96 h after the intraplantar injection of FCA or saline. The rats were placed in an acrylic box with a glass pane floor, and the plantar surface of their right hindpaw was exposed to a beam of infrared radiation (Ugo Basile, Stoelting, Chicago, IL). The latency of paw withdrawal was automatically measured by the apparatus.
Paw withdrawal latencies were recorded at an infrared intensity of 70 W twice per experimental session, separated by a minimum interval of 5 min. Minimum and maximum limits for paw withdrawal latency were assigned at 1 and 30 s, respectively. Furthermore, six rats from each experimental group were given naloxone at 0.5 mg/kg intraperitoneally. The withdrawal latency was determined by plantar test before naloxone administration as well as 30 min post-injection.
Histological Analysis
After 1 day of LLLT (n ϭ 3) or placebo (n ϭ 3) treatment, six rats were anesthetized with sevoflurane and each transcardially perfused with 60 mL of warm saline, followed by 300 mL of 10% (w/v) formaldehyde. The hindpaws were removed, immediately immersed in 10% buffered formalin, embedded in paraffin, and cut into 4 m thick sections. Paraffin sections were routinely stained with hematoxylin and eosin (H&E). Specimen preparation and H&E staining were performed in the same manner for the normal group (n ϭ 3).
Immunohistochemistry
After 1 day of LLLT (n ϭ 3) or placebo (n ϭ 3) treatment, another six rats were also anesthetized and transcardially perfused with 60 mL of warm saline, followed by 300 mL of 0.16 M phosphate buffer solution (pH 6.9) containing 4% (w/v) paraformaldehyde and 0.2% (v/v) picric acid. The hindpaws were removed, post-fixed for 24 h, and sunk in serial solutions of 10%, 15%, and 20% (w/v) sucrose at 4°C for 24 h. The tissue was embedded in OCT Tissue Tek compound (Miles Scientific, Paris, France), frozen and cut into 7 m thick sections. The sections were incubated overnight with anti-␤-endorphin (1:1000; Peninsula Laboratories, San Carlos, CA), incubated for 90 min with the appropriate biotinylated secondary antibody and avidin-biotin-conjugated peroxidase, washed, and stained for 3 to 5 min with 3Ј, 3Ј-diaminobenzidine tetrahydrochloride containing 0.01% H 2 O 2 in 0.05 M Tris-buffered saline (pH 7.6). After development, the slides were counterstained with Mayer's hematoxylin and mounted. 
Cell Culture and Media
Primary cultures of blood cells from experimental rats were used for in vitro experiments. Blood cells were maintained in RPMI 1640 medium containing 5% heat-inactive fetal bovine serum and antibiotics at 37°C under 5% CO 2 with ConA. Cells were cultured in 16.3 mm dishes containing 2 mL medium, and collected for reverse transcription-polymerase chain reaction (RT-PCR) after 5 min of LLLT irradiation, giving a total dose of 300 J.
RT-PCR
RT-PCR was used to quantitatively assess changes in CRF or POMC mRNA. RNA was extracted from blood cells or the hindpaws on the first and third day after FCA treatment, using the acid guanidinium thiocyanate-phenol-chloroform method. 24 RNA concentration was determined using a spectrophotometer DU640 (Beckman, Fullerton, CA) at 260 nm. First strand cDNA synthesis from 1 g initial total RNA and subsequent PCR were conducted using a commercial RT-PCR kit (Toyobo CO, Tokyo) on a GeneAmp PCR System 2400 (Perkin-Elmer, Wellesley, MA). Primers were designed and PCR conditions optimized for each target amplicon. Specific primers used were 5ЈCAGAACAACAGTGCGGGCTCA and 5ЈGGAAAAA-GTTAGCCGCAGCCT for CRF; 5ЈGGCCTTTCCCCTA-GAGTTCA and 5ЈTTGATGATGGCGTTCTTGAA for POMC; and 5ЈGTTCCGATGCCCCGAGGATCT and 5ЈGCATTTGCGGTGCACGATGGA for ␤-actin. PCR products were confirmed by electrophoresis on 1.5% agarose gels, followed by staining with ethidium bromide.
Images of the PCR amplicons were scanned and analyzed by the NIH Image 1.63 software program (Research Services Branch, Bethesda, MD). Band intensities were normalized to ␤-actin.
Statistical Analysis
These data were analyzed by an analysis of variance (ANOVA). Single comparisons used one-way ANOVA whereas statistical significance of differences between two comparisons was determined by two-way ANOVA. The significance level was set at P Ͻ 0.05.
RESULTS
Effects of LLLT on POMC and CRF mRNA Expression in Blood Cells
To better understand the physiological consequences of LLLT, we first examined its effect on rat blood cells in vitro. Before exposure of blood cells to LLLT, neither POMC nor CRF mRNA were detectable. After exposure of blood cells to LLLT for 12 or 24 h, both POMC and CRF mRNA expression increased, as compared to the control placebo-treated group (Fig. 1) . Such an increase demonstrated that LLLT exposure induces both POMC and CRF in blood cells.
Histological Analysis of Tissue Inflammation
On day 2, histological analysis using H&E staining revealed little accumulation of inflammatory cells in the hindpaw plantar tissue of the normal group treated with saline. In contrast, similar levels of inflammatory response were noted in rats injected with FCA, followed by either placebo or LLLT (Fig. 2) .
Pain Withdrawal Latency Changes in Rats After FCA Treatment and Analgesic Effects of LLLT
As an inverse measure of pain, withdrawal latency was significantly reduced at 12 h in rats receiving FCA and placebo treatment compared with those injected with only saline. Furthermore, the LLLT group exhibited a significant increase in withdrawal latency at 24 h after treatment in comparison to the control placebo-treated group, although no significant difference was observed at 12 h. Moreover, the significant analgesia induced by LLLT continued past 48 and 72 h. Hence, LLLT to blood significantly reduced FCA-induced hindpaw pain (P Ͻ 0.05) (Fig. 3A) . We also examined the relation between analgesia and the amount of LLLT administered. Reducing the LLLT exposure weakened the analgesic effect whereas a higher frequency of LLLT correlated with a greater analgesic effect at 24 h. Therefore, LLLT seemed to exert an analgesic effect on blood cells in a dosedependent manner (Fig. 3B ).
Effect of Naloxone on the Analgesic Action of LLLT
To verify that LLLT exerts an effect on endogenous analgesia, we antagonized opioid receptors with naloxone. Naloxone transiently reversed the analgesic effect induced by LLLT, reducing the withdrawal latency to a level comparable with that of the control group (P Ͻ 0.05) (Fig. 4) .
Immunohistochemical Analysis of ␤-endorphin Secreting Cells
Immunohistochemical analysis revealed slight accumulation of ␤-endorphin-positive cells in tissue from the control group after FCA injection. However, significantly more ␤-endorphin-positive cells were observed in tissue from the LLLT group (Fig. 5) .
DISCUSSION
LLLT has been reported to reduce pain in several model systems. 24 -26 Recently, studies suggested that LLLT functions to reduce inflammatory cells. 27, 28 Mechanistically, LLLT inhibits various inflammatory mediators, including tumor necrosis factor-␣. 24, 29 In addition, LLLT has been shown to reduce cyclooxygenase-2 mRNA. 30 The cyclooxygenase-2 pathway is activated in stress conditions, such as inflammation. 30 These antiinflammatory mechanisms may be related to the analgesic effect of LLLT. In the present study, we demonstrated that LLLT irradiation of blood exerted an analgesic effect on thermal nociceptive stimuli in the inflamed paw tissue of rats that can be transiently antagonized by naloxone. We further demonstrated an upregulation of peripheral opioid precursor expression in blood cells, suggestive of a direct induction by LLLT to mediate analgesia. Hence, LLLT not only exerts an antiinflammatory effect but also induces peripheral opioids to mediate analgesia.
Our hypothesis is supported by several lines of evidence. LLLT enhanced the expression of ␤-endorphins to the blood cells. Beta-endorphins, as endogenous opioids, have a potent analgesic action. 31 Moreover, ␤-endorphins and other opioids were found to cause peripheral analgesia when its precursors, CRF and POMC, were expressed at peripherally inflamed sites. 17, 32, 33 In our study, LLLT irradiation of blood was associated with expression of CRF and POMC mRNA. Indeed, LLLT stimulated the release of corticosteroid hormones in the inflammatory tissue in agreement with previously published work. 34 This was also demonstrated in vitro using cultured blood cells, in which POMC and CRF mRNA were detected after LLLT, suggesting a possible increase in ␤-endorphin precursors in the blood cells. This is the first study demonstrating that preirradiation of blood by LLLT enhances peripheral endogenous opioid analgesia. In addition, opioid receptors are important to the analgesic effect in inflammatory pain. 35 Treatment with LLLT might also be expected to produce peripheral analgesia in humans, since POMC and CRF mRNA expression are present in human blood cells. 36, 37 This finding suggests that one mechanism by which LLLT produces analgesia may be enhancement of peripheral opioids.
Peripheral opioid analgesia has received considerable attention as an endogenous pathway of inhibiting pain. Experimental studies using rats have reported that endogenous opioids are released from inflammatory cells, which act on opioid receptors on the peripheral sensory nerves. 12 In conclusion, the present study demonstrates that LLLT pre-irradiation of blood may enhance peripheral endogenous opioid analgesia. However, the mechanism of CRF and POMC induction by LLLT remains unknown and should be examined further.
